Top Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More

105
3
Favorite

Top Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More

TheFly2023-04-13

Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target of $120, up from $105. The analyst sees TKO, the combined WWE and UFC business, as offering an ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

105

Report

Comment（3）

Sphere
·2023-04-14
Hmm
Reply
5
Report
myLaohor
·2023-04-13
Nice
Reply
9
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1149609772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-13 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149609772","market":"us","top_or_hot":-1,"title":"Top Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More","media":"TheFly","content":"<div>\n<p>Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target of $120, up from $105. The analyst sees TKO, the combined WWE and UFC business, as offering an ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3694038&headline=WWE;SHOO;SPWR;GM;CRSP;FSLR;XOM;CVX;LXU;LYB;JD;AVGO;PLRX;MRK-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic\">Source Link</a>\n\n</div>\n","source":"lsy1666364704704","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-13 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3694038&headline=WWE;SHOO;SPWR;GM;CRSP;FSLR;XOM;CVX;LXU;LYB;JD;AVGO;PLRX;MRK-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic><strong>TheFly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target of $120, up from $105. The analyst sees TKO, the combined WWE and UFC business, as offering an ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3694038&headline=WWE;SHOO;SPWR;GM;CRSP;FSLR;XOM;CVX;LXU;LYB;JD;AVGO;PLRX;MRK-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XOM","symbol_name":"埃克森美孚","start_time":0,"source_url":"https://thefly.com/landingPageNews.php?id=3694038&headline=WWE;SHOO;SPWR;GM;CRSP;FSLR;XOM;CVX;LXU;LYB;JD;AVGO;PLRX;MRK-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic","article_id":"1149609772","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149609772","pubTimestamp":1681395769,"sourceInfo":{"source_id":"lsy1666364704704","name":"thefly"},"weMediaInfo":null,"summary":"Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target","collect":0,"end_time":0,"defaultTopTitle":"thefly.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"XOM":"埃克森美孚","CVX":"雪佛龙","GM":"通用汽车","JD":"京东"},"translate_title":"华尔街的热门电话：雪佛龙、埃克森美孚、京东等","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVX":0.9,"GM":0.9,"JD":0.9,"XOM":0.9},"content_text":"Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target of $120, up from $105. The analyst sees TKO, the combined WWE and UFC business, as offering an attractive risk/reward given the \"secular tailwinds\" behind sports and entertainment media rights revenues, live content, and the \"defensive characteristics\" of largely contracted revenue growth.Citi upgraded Steven Madden (SHOO) to Buy from Neutral with a price target of $42, up from $40. The analyst also opened a \"positive catalyst watch\" on the shares ahead of the company's Q1 results on April 26. The firm anticipates a \"modest\" Q1 beat, but more importantly, expects management to talk \"more optimistically\" about wholesale trends, suggesting upside in Q2 and fiscal 2023.BofA upgraded SunPower (SPWR) to Neutral from Underperform with a price target of $15, up from $14. The analyst sees improved visibility into the company's 2023 profitability.Scotiabank upgraded Chevron (CVX) to Outperform from Sector Perform with a price target of $200, up from $195. The firm sees the risk/reward for Chevron having improved.Citi analyst Andrew Baum upgraded Merck (MRK) to Buy from Neutral with a price target of $130, up from $105. The analyst \"materially\" increased estimates for Merck to reflect its novel antibody drug conjugates for cancer MK-2870/SKB-264 and cardiology agents sotatercept and MK-0616.Top 5 Downgrades:Deutsche Bank downgraded First Solar (FSLR) to Hold from Buy with a price target of $230, up from $190. Now is an opportune moment for investors to look for better risk/reward elsewhere in the solar space after First Solar's stock rally of 45% since early November, the analyst tells investors in a research note.Scotiabank downgraded Exxon Mobil (XOM) to Sector Perform from Outperform with a price target of $135, down from $140. Citing Chevron's higher oil beta among the super majors, the firm also notes that Exxon shares have further outperformed those of its peer since mid-January after having outperformed Chevron by 27% in 2022 and 9% in 2021.Jefferies downgraded LSB Industries (LXU) to Hold from Buy with a price target of $10, down from $20. The sequential decline in ammonia prices has accelerated, aggravated by delays in pre-planting ammonia applications, and with persistent weakness in natural gas prices in Europe and risks to industrial demand later this year, fly-ups appear unlikely until 2025-2026 at the earliest, the analyst tells investors in a research note.Jefferies downgraded LyondellBasell (LYB) to Hold from Buy with a price target of $90, down from $113. With OPEC's production cut and U.S. natural gas testing $2 per MMBTU, the U.S. shale advantage thesis has played out, the analyst said.UBS downgraded JD.com (JD) to Neutral from Buy with a price target of $43, down from $60. JD lacks exposure to the faster growing segments of e-commerce, argues the firm, which believes JD could undergo a longer adjustment period in order to improve its product selection and user experience for value oriented shoppers to better compete in the long-term with Pinduoduo (PDD), Alibaba (BABA) and Douyin.Top 5 Initiations:Mizuho initiated coverage of General Motors (GM) with a Neutral rating and $39 price target. While noting that GM has a broad consumer-commercial EV portfolio, the firm notes this is currently only about 2% of the mix and while it sees GM being positioned \"well for the next decade of EVs,\" a transition from a profitable, roughly 98% ICE portfolio to an EV portfolio that currently has a negative 15%-30% gross margin \"poses significant challenges.\"Cantor Fitzgerald initiated coverage of Crispr Therapeutics (CRSP) with an Overweight rating and $72 price target. The analyst says Crispr \"stands out\" as an \"interesting\" gene editing play for 2023.Canaccord initiated coverage of Intellia Therapeutics (NTLA) with a Buy rating and $66 price target. The company's focus on in-vivo gene editing in large, rare indications was \"perhaps not the fastest path to the clinic\" relative to its early CRISPR peer companies, but Intellia's \"methodical approach has paid off,\" the analyst tells investors.Benchmark initiated coverage of Broadcom (AVGO) with a Buy rating and $770 price target. Broadcom became the second largest market cap company in the chip industry following its 2017 acquisition of Brocade and now it remains number two, trailing only Nvidia (NVDA), following years of organic growth and \"dozens of successful acquisitions.\"Baird initiated coverage of Pliant Therapeutics (PLRX) with an Outperform rating and $44 price target. The analyst contends that bexotegrast is a promising agent for idiopathic pulmonary fibrosis, supported by the 12-week phase 2a data released by Pliant in January 2023.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9945810900,"gmtCreate":1681426115301,"gmtModify":1681426118690,"author":{"id":"3573432013960035","authorId":"3573432013960035","name":"Sphere","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":0},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945810900","repostId":1149609772,"repostType":2,"repost":{"id":"1149609772","pubTimestamp":1681395769,"share":"https://www.laohu8.com/m/news/1149609772?lang=&edition=full","pubTime":"2023-04-13 22:22","market":"us","language":"en","title":"Top Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More","url":"https://stock-news.laohu8.com/highlight/detail?id=1149609772","media":"TheFly","summary":"Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target","content":"<html><head></head><body><p><strong>Top 5 Upgrades:</strong></p><ul><li><p>Morgan Stanley upgraded<strong> WWE</strong> (WWE) to Overweight from Equal Weight with a price target of $120, up from $105. The analyst sees TKO, the combined WWE and UFC business, as offering an attractive risk/reward given the &#34;secular tailwinds&#34; behind sports and entertainment media rights revenues, live content, and the &#34;defensive characteristics&#34; of largely contracted revenue growth.</p></li><li><p>Citi upgraded <strong>Steven Madden</strong> (SHOO) to Buy from Neutral with a price target of $42, up from $40. The analyst also opened a &#34;positive catalyst watch&#34; on the shares ahead of the company&#39;s Q1 results on April 26. The firm anticipates a &#34;modest&#34; Q1 beat, but more importantly, expects management to talk &#34;more optimistically&#34; about wholesale trends, suggesting upside in Q2 and fiscal 2023.</p></li><li><p>BofA upgraded <strong>SunPower </strong>(SPWR) to Neutral from Underperform with a price target of $15, up from $14. The analyst sees improved visibility into the company&#39;s 2023 profitability.</p></li><li><p>Scotiabank upgraded <strong>Chevron</strong> (CVX) to Outperform from Sector Perform with a price target of $200, up from $195. The firm sees the risk/reward for Chevron having improved.</p></li><li><p>Citi analyst Andrew Baum upgraded <strong>Merck </strong>(MRK) to Buy from Neutral with a price target of $130, up from $105. The analyst &#34;materially&#34; increased estimates for Merck to reflect its novel antibody drug conjugates for cancer MK-2870/SKB-264 and cardiology agents sotatercept and MK-0616.</p></li></ul><p><strong>Top 5 Downgrades:</strong></p><ul><li><p>Deutsche Bank downgraded <strong>First Solar </strong>(FSLR) to Hold from Buy with a price target of $230, up from $190. Now is an opportune moment for investors to look for better risk/reward elsewhere in the solar space after First Solar&#39;s stock rally of 45% since early November, the analyst tells investors in a research note.</p></li><li><p>Scotiabank downgraded <strong>Exxon Mobil </strong>(XOM) to Sector Perform from Outperform with a price target of $135, down from $140. Citing Chevron&#39;s higher oil beta among the super majors, the firm also notes that Exxon shares have further outperformed those of its peer since mid-January after having outperformed Chevron by 27% in 2022 and 9% in 2021.</p></li><li><p>Jefferies downgraded <strong>LSB Industries</strong> (LXU) to Hold from Buy with a price target of $10, down from $20. The sequential decline in ammonia prices has accelerated, aggravated by delays in pre-planting ammonia applications, and with persistent weakness in natural gas prices in Europe and risks to industrial demand later this year, fly-ups appear unlikely until 2025-2026 at the earliest, the analyst tells investors in a research note.</p></li><li><p>Jefferies downgraded <strong>LyondellBasell</strong> (LYB) to Hold from Buy with a price target of $90, down from $113. With OPEC&#39;s production cut and U.S. natural gas testing $2 per MMBTU, the U.S. shale advantage thesis has played out, the analyst said.</p></li><li><p>UBS downgraded <strong>JD.com</strong> (JD) to Neutral from Buy with a price target of $43, down from $60. JD lacks exposure to the faster growing segments of e-commerce, argues the firm, which believes JD could undergo a longer adjustment period in order to improve its product selection and user experience for value oriented shoppers to better compete in the long-term with Pinduoduo (PDD), Alibaba (BABA) and Douyin.</p></li></ul><p><strong>Top 5 Initiations:</strong></p><ul><li><p>Mizuho initiated coverage of <strong>General Motors </strong>(GM) with a Neutral rating and $39 price target. While noting that GM has a broad consumer-commercial EV portfolio, the firm notes this is currently only about 2% of the mix and while it sees GM being positioned &#34;well for the next decade of EVs,&#34; a transition from a profitable, roughly 98% ICE portfolio to an EV portfolio that currently has a negative 15%-30% gross margin &#34;poses significant challenges.&#34;</p></li><li><p>Cantor Fitzgerald initiated coverage of <strong>Crispr Therapeutics</strong> (CRSP) with an Overweight rating and $72 price target. The analyst says Crispr &#34;stands out&#34; as an &#34;interesting&#34; gene editing play for 2023.</p></li><li><p>Canaccord initiated coverage of<strong> Intellia Therapeutics</strong> (NTLA) with a Buy rating and $66 price target. The company&#39;s focus on in-vivo gene editing in large, rare indications was &#34;perhaps not the fastest path to the clinic&#34; relative to its early CRISPR peer companies, but Intellia&#39;s &#34;methodical approach has paid off,&#34; the analyst tells investors.</p></li><li><p>Benchmark initiated coverage of <strong>Broadcom</strong> (AVGO) with a Buy rating and $770 price target. Broadcom became the second largest market cap company in the chip industry following its 2017 acquisition of Brocade and now it remains number two, trailing only Nvidia (NVDA), following years of organic growth and &#34;dozens of successful acquisitions.&#34;</p></li><li><p>Baird initiated coverage of <strong>Pliant Therapeutics </strong>(PLRX) with an Outperform rating and $44 price target. The analyst contends that bexotegrast is a promising agent for idiopathic pulmonary fibrosis, supported by the 12-week phase 2a data released by Pliant in January 2023.</p></li></ul></body></html>","source":"lsy1666364704704","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-13 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3694038&headline=WWE;SHOO;SPWR;GM;CRSP;FSLR;XOM;CVX;LXU;LYB;JD;AVGO;PLRX;MRK-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic><strong>TheFly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target of $120, up from $105. The analyst sees TKO, the combined WWE and UFC business, as offering an ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3694038&headline=WWE;SHOO;SPWR;GM;CRSP;FSLR;XOM;CVX;LXU;LYB;JD;AVGO;PLRX;MRK-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车","XOM":"埃克森美孚","JD":"京东","CVX":"雪佛龙"},"source_url":"https://thefly.com/landingPageNews.php?id=3694038&headline=WWE;SHOO;SPWR;GM;CRSP;FSLR;XOM;CVX;LXU;LYB;JD;AVGO;PLRX;MRK-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149609772","content_text":"Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target of $120, up from $105. The analyst sees TKO, the combined WWE and UFC business, as offering an attractive risk/reward given the \"secular tailwinds\" behind sports and entertainment media rights revenues, live content, and the \"defensive characteristics\" of largely contracted revenue growth.Citi upgraded Steven Madden (SHOO) to Buy from Neutral with a price target of $42, up from $40. The analyst also opened a \"positive catalyst watch\" on the shares ahead of the company's Q1 results on April 26. The firm anticipates a \"modest\" Q1 beat, but more importantly, expects management to talk \"more optimistically\" about wholesale trends, suggesting upside in Q2 and fiscal 2023.BofA upgraded SunPower (SPWR) to Neutral from Underperform with a price target of $15, up from $14. The analyst sees improved visibility into the company's 2023 profitability.Scotiabank upgraded Chevron (CVX) to Outperform from Sector Perform with a price target of $200, up from $195. The firm sees the risk/reward for Chevron having improved.Citi analyst Andrew Baum upgraded Merck (MRK) to Buy from Neutral with a price target of $130, up from $105. The analyst \"materially\" increased estimates for Merck to reflect its novel antibody drug conjugates for cancer MK-2870/SKB-264 and cardiology agents sotatercept and MK-0616.Top 5 Downgrades:Deutsche Bank downgraded First Solar (FSLR) to Hold from Buy with a price target of $230, up from $190. Now is an opportune moment for investors to look for better risk/reward elsewhere in the solar space after First Solar's stock rally of 45% since early November, the analyst tells investors in a research note.Scotiabank downgraded Exxon Mobil (XOM) to Sector Perform from Outperform with a price target of $135, down from $140. Citing Chevron's higher oil beta among the super majors, the firm also notes that Exxon shares have further outperformed those of its peer since mid-January after having outperformed Chevron by 27% in 2022 and 9% in 2021.Jefferies downgraded LSB Industries (LXU) to Hold from Buy with a price target of $10, down from $20. The sequential decline in ammonia prices has accelerated, aggravated by delays in pre-planting ammonia applications, and with persistent weakness in natural gas prices in Europe and risks to industrial demand later this year, fly-ups appear unlikely until 2025-2026 at the earliest, the analyst tells investors in a research note.Jefferies downgraded LyondellBasell (LYB) to Hold from Buy with a price target of $90, down from $113. With OPEC's production cut and U.S. natural gas testing $2 per MMBTU, the U.S. shale advantage thesis has played out, the analyst said.UBS downgraded JD.com (JD) to Neutral from Buy with a price target of $43, down from $60. JD lacks exposure to the faster growing segments of e-commerce, argues the firm, which believes JD could undergo a longer adjustment period in order to improve its product selection and user experience for value oriented shoppers to better compete in the long-term with Pinduoduo (PDD), Alibaba (BABA) and Douyin.Top 5 Initiations:Mizuho initiated coverage of General Motors (GM) with a Neutral rating and $39 price target. While noting that GM has a broad consumer-commercial EV portfolio, the firm notes this is currently only about 2% of the mix and while it sees GM being positioned \"well for the next decade of EVs,\" a transition from a profitable, roughly 98% ICE portfolio to an EV portfolio that currently has a negative 15%-30% gross margin \"poses significant challenges.\"Cantor Fitzgerald initiated coverage of Crispr Therapeutics (CRSP) with an Overweight rating and $72 price target. The analyst says Crispr \"stands out\" as an \"interesting\" gene editing play for 2023.Canaccord initiated coverage of Intellia Therapeutics (NTLA) with a Buy rating and $66 price target. The company's focus on in-vivo gene editing in large, rare indications was \"perhaps not the fastest path to the clinic\" relative to its early CRISPR peer companies, but Intellia's \"methodical approach has paid off,\" the analyst tells investors.Benchmark initiated coverage of Broadcom (AVGO) with a Buy rating and $770 price target. Broadcom became the second largest market cap company in the chip industry following its 2017 acquisition of Brocade and now it remains number two, trailing only Nvidia (NVDA), following years of organic growth and \"dozens of successful acquisitions.\"Baird initiated coverage of Pliant Therapeutics (PLRX) with an Outperform rating and $44 price target. The analyst contends that bexotegrast is a promising agent for idiopathic pulmonary fibrosis, supported by the 12-week phase 2a data released by Pliant in January 2023.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9945110554,"gmtCreate":1681400900878,"gmtModify":1681400904894,"author":{"id":"3575311552142146","authorId":"3575311552142146","name":"myLaohor","avatar":"https://static.tigerbbs.com/1ee11e351b6ef6ec0c8751da005b4a83","vip":1,"hat":"https://static.tigerbbs.com/d30fc324d24ff33075e053005564f0df","crmLevel":1,"crmLevelSwitch":0},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945110554","repostId":1149609772,"repostType":2,"repost":{"id":"1149609772","pubTimestamp":1681395769,"share":"https://www.laohu8.com/m/news/1149609772?lang=&edition=full","pubTime":"2023-04-13 22:22","market":"us","language":"en","title":"Top Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More","url":"https://stock-news.laohu8.com/highlight/detail?id=1149609772","media":"TheFly","summary":"Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target","content":"<html><head></head><body><p><strong>Top 5 Upgrades:</strong></p><ul><li><p>Morgan Stanley upgraded<strong> WWE</strong> (WWE) to Overweight from Equal Weight with a price target of $120, up from $105. The analyst sees TKO, the combined WWE and UFC business, as offering an attractive risk/reward given the &#34;secular tailwinds&#34; behind sports and entertainment media rights revenues, live content, and the &#34;defensive characteristics&#34; of largely contracted revenue growth.</p></li><li><p>Citi upgraded <strong>Steven Madden</strong> (SHOO) to Buy from Neutral with a price target of $42, up from $40. The analyst also opened a &#34;positive catalyst watch&#34; on the shares ahead of the company&#39;s Q1 results on April 26. The firm anticipates a &#34;modest&#34; Q1 beat, but more importantly, expects management to talk &#34;more optimistically&#34; about wholesale trends, suggesting upside in Q2 and fiscal 2023.</p></li><li><p>BofA upgraded <strong>SunPower </strong>(SPWR) to Neutral from Underperform with a price target of $15, up from $14. The analyst sees improved visibility into the company&#39;s 2023 profitability.</p></li><li><p>Scotiabank upgraded <strong>Chevron</strong> (CVX) to Outperform from Sector Perform with a price target of $200, up from $195. The firm sees the risk/reward for Chevron having improved.</p></li><li><p>Citi analyst Andrew Baum upgraded <strong>Merck </strong>(MRK) to Buy from Neutral with a price target of $130, up from $105. The analyst &#34;materially&#34; increased estimates for Merck to reflect its novel antibody drug conjugates for cancer MK-2870/SKB-264 and cardiology agents sotatercept and MK-0616.</p></li></ul><p><strong>Top 5 Downgrades:</strong></p><ul><li><p>Deutsche Bank downgraded <strong>First Solar </strong>(FSLR) to Hold from Buy with a price target of $230, up from $190. Now is an opportune moment for investors to look for better risk/reward elsewhere in the solar space after First Solar&#39;s stock rally of 45% since early November, the analyst tells investors in a research note.</p></li><li><p>Scotiabank downgraded <strong>Exxon Mobil </strong>(XOM) to Sector Perform from Outperform with a price target of $135, down from $140. Citing Chevron&#39;s higher oil beta among the super majors, the firm also notes that Exxon shares have further outperformed those of its peer since mid-January after having outperformed Chevron by 27% in 2022 and 9% in 2021.</p></li><li><p>Jefferies downgraded <strong>LSB Industries</strong> (LXU) to Hold from Buy with a price target of $10, down from $20. The sequential decline in ammonia prices has accelerated, aggravated by delays in pre-planting ammonia applications, and with persistent weakness in natural gas prices in Europe and risks to industrial demand later this year, fly-ups appear unlikely until 2025-2026 at the earliest, the analyst tells investors in a research note.</p></li><li><p>Jefferies downgraded <strong>LyondellBasell</strong> (LYB) to Hold from Buy with a price target of $90, down from $113. With OPEC&#39;s production cut and U.S. natural gas testing $2 per MMBTU, the U.S. shale advantage thesis has played out, the analyst said.</p></li><li><p>UBS downgraded <strong>JD.com</strong> (JD) to Neutral from Buy with a price target of $43, down from $60. JD lacks exposure to the faster growing segments of e-commerce, argues the firm, which believes JD could undergo a longer adjustment period in order to improve its product selection and user experience for value oriented shoppers to better compete in the long-term with Pinduoduo (PDD), Alibaba (BABA) and Douyin.</p></li></ul><p><strong>Top 5 Initiations:</strong></p><ul><li><p>Mizuho initiated coverage of <strong>General Motors </strong>(GM) with a Neutral rating and $39 price target. While noting that GM has a broad consumer-commercial EV portfolio, the firm notes this is currently only about 2% of the mix and while it sees GM being positioned &#34;well for the next decade of EVs,&#34; a transition from a profitable, roughly 98% ICE portfolio to an EV portfolio that currently has a negative 15%-30% gross margin &#34;poses significant challenges.&#34;</p></li><li><p>Cantor Fitzgerald initiated coverage of <strong>Crispr Therapeutics</strong> (CRSP) with an Overweight rating and $72 price target. The analyst says Crispr &#34;stands out&#34; as an &#34;interesting&#34; gene editing play for 2023.</p></li><li><p>Canaccord initiated coverage of<strong> Intellia Therapeutics</strong> (NTLA) with a Buy rating and $66 price target. The company&#39;s focus on in-vivo gene editing in large, rare indications was &#34;perhaps not the fastest path to the clinic&#34; relative to its early CRISPR peer companies, but Intellia&#39;s &#34;methodical approach has paid off,&#34; the analyst tells investors.</p></li><li><p>Benchmark initiated coverage of <strong>Broadcom</strong> (AVGO) with a Buy rating and $770 price target. Broadcom became the second largest market cap company in the chip industry following its 2017 acquisition of Brocade and now it remains number two, trailing only Nvidia (NVDA), following years of organic growth and &#34;dozens of successful acquisitions.&#34;</p></li><li><p>Baird initiated coverage of <strong>Pliant Therapeutics </strong>(PLRX) with an Outperform rating and $44 price target. The analyst contends that bexotegrast is a promising agent for idiopathic pulmonary fibrosis, supported by the 12-week phase 2a data released by Pliant in January 2023.</p></li></ul></body></html>","source":"lsy1666364704704","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Calls on Wall Street: Chevron, Exxon Mobil, JD.com and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-13 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3694038&headline=WWE;SHOO;SPWR;GM;CRSP;FSLR;XOM;CVX;LXU;LYB;JD;AVGO;PLRX;MRK-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic><strong>TheFly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target of $120, up from $105. The analyst sees TKO, the combined WWE and UFC business, as offering an ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3694038&headline=WWE;SHOO;SPWR;GM;CRSP;FSLR;XOM;CVX;LXU;LYB;JD;AVGO;PLRX;MRK-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车","XOM":"埃克森美孚","JD":"京东","CVX":"雪佛龙"},"source_url":"https://thefly.com/landingPageNews.php?id=3694038&headline=WWE;SHOO;SPWR;GM;CRSP;FSLR;XOM;CVX;LXU;LYB;JD;AVGO;PLRX;MRK-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149609772","content_text":"Top 5 Upgrades:Morgan Stanley upgraded WWE (WWE) to Overweight from Equal Weight with a price target of $120, up from $105. The analyst sees TKO, the combined WWE and UFC business, as offering an attractive risk/reward given the \"secular tailwinds\" behind sports and entertainment media rights revenues, live content, and the \"defensive characteristics\" of largely contracted revenue growth.Citi upgraded Steven Madden (SHOO) to Buy from Neutral with a price target of $42, up from $40. The analyst also opened a \"positive catalyst watch\" on the shares ahead of the company's Q1 results on April 26. The firm anticipates a \"modest\" Q1 beat, but more importantly, expects management to talk \"more optimistically\" about wholesale trends, suggesting upside in Q2 and fiscal 2023.BofA upgraded SunPower (SPWR) to Neutral from Underperform with a price target of $15, up from $14. The analyst sees improved visibility into the company's 2023 profitability.Scotiabank upgraded Chevron (CVX) to Outperform from Sector Perform with a price target of $200, up from $195. The firm sees the risk/reward for Chevron having improved.Citi analyst Andrew Baum upgraded Merck (MRK) to Buy from Neutral with a price target of $130, up from $105. The analyst \"materially\" increased estimates for Merck to reflect its novel antibody drug conjugates for cancer MK-2870/SKB-264 and cardiology agents sotatercept and MK-0616.Top 5 Downgrades:Deutsche Bank downgraded First Solar (FSLR) to Hold from Buy with a price target of $230, up from $190. Now is an opportune moment for investors to look for better risk/reward elsewhere in the solar space after First Solar's stock rally of 45% since early November, the analyst tells investors in a research note.Scotiabank downgraded Exxon Mobil (XOM) to Sector Perform from Outperform with a price target of $135, down from $140. Citing Chevron's higher oil beta among the super majors, the firm also notes that Exxon shares have further outperformed those of its peer since mid-January after having outperformed Chevron by 27% in 2022 and 9% in 2021.Jefferies downgraded LSB Industries (LXU) to Hold from Buy with a price target of $10, down from $20. The sequential decline in ammonia prices has accelerated, aggravated by delays in pre-planting ammonia applications, and with persistent weakness in natural gas prices in Europe and risks to industrial demand later this year, fly-ups appear unlikely until 2025-2026 at the earliest, the analyst tells investors in a research note.Jefferies downgraded LyondellBasell (LYB) to Hold from Buy with a price target of $90, down from $113. With OPEC's production cut and U.S. natural gas testing $2 per MMBTU, the U.S. shale advantage thesis has played out, the analyst said.UBS downgraded JD.com (JD) to Neutral from Buy with a price target of $43, down from $60. JD lacks exposure to the faster growing segments of e-commerce, argues the firm, which believes JD could undergo a longer adjustment period in order to improve its product selection and user experience for value oriented shoppers to better compete in the long-term with Pinduoduo (PDD), Alibaba (BABA) and Douyin.Top 5 Initiations:Mizuho initiated coverage of General Motors (GM) with a Neutral rating and $39 price target. While noting that GM has a broad consumer-commercial EV portfolio, the firm notes this is currently only about 2% of the mix and while it sees GM being positioned \"well for the next decade of EVs,\" a transition from a profitable, roughly 98% ICE portfolio to an EV portfolio that currently has a negative 15%-30% gross margin \"poses significant challenges.\"Cantor Fitzgerald initiated coverage of Crispr Therapeutics (CRSP) with an Overweight rating and $72 price target. The analyst says Crispr \"stands out\" as an \"interesting\" gene editing play for 2023.Canaccord initiated coverage of Intellia Therapeutics (NTLA) with a Buy rating and $66 price target. The company's focus on in-vivo gene editing in large, rare indications was \"perhaps not the fastest path to the clinic\" relative to its early CRISPR peer companies, but Intellia's \"methodical approach has paid off,\" the analyst tells investors.Benchmark initiated coverage of Broadcom (AVGO) with a Buy rating and $770 price target. Broadcom became the second largest market cap company in the chip industry following its 2017 acquisition of Brocade and now it remains number two, trailing only Nvidia (NVDA), following years of organic growth and \"dozens of successful acquisitions.\"Baird initiated coverage of Pliant Therapeutics (PLRX) with an Outperform rating and $44 price target. The analyst contends that bexotegrast is a promising agent for idiopathic pulmonary fibrosis, supported by the 12-week phase 2a data released by Pliant in January 2023.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":105,"commentSize":3,"repostSize":4,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}